GSK-Vir’s sotrovimab authorised in US to treat Covid-19
In Phase 3 COMET-ICE trial, sotrovimab reduced 85% risk of hospitalisation or death in high-risk adult patients compared…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 May 21
In Phase 3 COMET-ICE trial, sotrovimab reduced 85% risk of hospitalisation or death in high-risk adult patients compared…
26 May 21
Venclyxto-based combination treatments are indicated for adults with newly diagnosed AML, who are not eligible for intensive chemotherapy
24 May 21
The US FDA has also approved Guardant Health's Guardant360 CDx liquid biopsy blood test as a companion diagnostic…
21 May 21
The FDA approval expands the role of Opdivo in earlier stages of the disease, with two indications across…
17 May 21
The US FDA approval of Empaveli is based on results from the head-to-head Phase 3 PEGASUS study
11 May 21
The FDA authorisation is based on data from a pivotal Phase 3 clinical trial, which enrolled 2,260 individuals…
10 May 21
The anti-Covid-19 oral drug has been developed by INMAS, a lab of DRDO, in partnership with Hyderabad-based Dr…
06 May 21
The approval is based on data from the Phase 3 clinical trial, which enrolled 2,260 adolescents aged 12…
06 May 21
The EC approval represents Tecentriq’s fourth indication in metastatic NSCLC and fifth indication in lung cancer overall in…
03 May 21
Farxiga is said to have reduced the risk of the composite of worsening of renal function, end-stage kidney…